Close Menu

NEW YORK (360Dx) – Zenosense on Wednesday announced that its joint venture called MIDS Medical has reached an agreement for up to $1.2 million in funding to further develop its handheld device for the early detection of a heart attack at the point of care.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.